Replies to post #74997 on Ocata Therapeutics Inc fka OCAT

[SMD2014]

Lasers. I really respect your opinion and all the important information that you bring to this board. Unfortunately I do not agree with you on the earlier approval. ACTC will take 150 patients - 50 patients SMD in the US - 50 patients SMD in the UK and 50 patients AMD in the USA.

I don't think that it will be a faster approval since they will need more patients to complete their statistics. Also, it will be unlikely that ACTC will treat excellent vision patients (early stage of the disease) in phase 2 since they will not put in danger the good vision of someone. AS I explained in my other posts, Phase 1 of SMD will stay stable for 10 years + without progression of the disease. ACTC will likely wait to obtain more results before treating such patients (like me...)

I guess we will be able to provide more information on the approval when ACTC will publish their criteria for the new enrollment.

Hope I am wrong but I prefer to be realistic. I believe totally in the treatment of ACTC but they need statistics and time before the approval. And I am pretty sure that the Phase II results will be the same as phase I. Miraculous.

[Bunk]

So where's the big money at if its 3k per?